文献速递类风湿关节炎脊柱关节炎

从全基因组关联研究到炎症性关节炎合理药物靶点优先排序

From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis.
PubMed 文献 · Lancet Rheumatol · 2019-12-10

综述指出炎症性关节炎相关疾病已有81项高质量GWAS收录于GWAS目录,但遗传发现向药物靶点发现的转化仍然不足;阿巴西普和司库奇尤单抗的研发仅部分受遗传关联驱动。文章讨论了遗传结构知识有限、需识别基因调控网络和评估靶点可成药性等障碍,并提出功能基因组学与网络信息连接变异与核心基因、识别通路交叉点等新机会。

要点

  • 81项高质量GWAS已收录于GWAS目录,但遗传发现向药物靶点发现转化仍不足。
  • 尚无人类遗传发现完全驱动炎症性关节炎药物开发,阿巴西普和司库奇尤单抗仅部分受遗传关联驱动。
  • 功能基因组学与网络信息可连接遗传变异与核心基因及外周基因,通路交叉点可提示治疗干预关键点。

核心结论

  • 早期识别经遗传学验证的药物靶点可提高晚期药物开发成功的机会,但目前GWAS发现向合理药物靶点发现的转化仍然不足。

研究设计与样本

  • 本文为综述,汇总了GWAS目录中81项与炎症性关节炎相关疾病的高质量全基因组关联研究。

主要发现

  • 尚无人类遗传发现完全驱动炎症性关节炎的药物开发,但遗传关联已部分驱动阿巴西普(CTLA-4-Ig)在类风湿关节炎和司库奇尤单抗(抗IL-23R)在强直性脊柱炎中的开发。

关键数值与推荐

  • GWAS目录已收录81项与炎症性关节炎相关疾病的高质量全基因组关联研究。

临床怎么用

  • 可利用功能基因组学将遗传变异链接到核心基因,再通过网络信息链接到与核心基因互连的外周基因,并识别生物通路间的交叉点以提示治疗干预关键点。

局限性

  • 对遗传关联背后的遗传结构和调控机制了解甚少,且需识别基因调控网络并评估靶点可成药性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early identification of genetically validated drug targets can increase the chances of successful late-stage drug development. 81 high-quality genome-wide association studies (GWAS) in diseases related to inflammatory arthritis have been curated into the GWAS catalogue; however, translation of genetic findings from GWAS into rational drug target discovery has been poor. No human genetic findings have completely driven drug development for inflammatory arthritis; however, genetic associations have partly driven the development of abatacept (CTLA-4-Ig) in rheumatoid arthritis and secukinumab (anti-IL-23R) in ankylosing spondylitis. Roadblocks to progress exist, including little knowledge of the genetic architecture and regulatory mechanisms underlying associations, and the need to identify gene regulatory networks and assess target tractability. New opportunities are arising that could maximise the informativeness of GWAS for drug target validation. Genetic variants can be linked to core genes by using functional genomics and then to peripheral genes interconnected to core genes using network information. Moreover, identification of crosstalk between biological pathways might highlight key points for therapeutic intervention.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fang H, Chen L, Knight JC, et al. From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis. Lancet Rheumatol. 2019. PMID: 38258277. doi:10.1016/S2665-9913(19)30134-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。